Tandem Diabetes Care (TNDM) Asset Writedowns and Impairment (2013 - 2026)

Tandem Diabetes Care's Asset Writedowns and Impairment history runs 14 years deep, the most recent figure standing at $2.1 million for Q1 2026.

• Quarterly Asset Writedowns and Impairment rose 47.38% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.2 million (down 29.69% YoY) and the FY2025 annual result came in at $9.5 million, down 5.02% from the prior year.
• Asset Writedowns and Impairment was $2.1 million for Q1 2026 at Tandem Diabetes Care, down from $2.8 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $12.7 million in Q2 2023 and bottomed at $346000.0 in Q1 2022.
• A 5-year average of $3.3 million and a median of $2.1 million in 2026 frame the typical range for Asset Writedowns and Impairment.
• Annual changes were most pronounced in 2023 — Asset Writedowns and Impairment jumped 1011.28% — and 2024, when it slumped 88.0%.
• Tandem Diabetes Care's Asset Writedowns and Impairment stood at $7.6 million in 2022, then slumped by 82.71% to $1.3 million in 2023, then jumped by 510.02% to $8.0 million in 2024, then sank by 65.15% to $2.8 million in 2025, then slipped by 24.16% to $2.1 million in 2026.
• Business Quant data shows TNDM's Asset Writedowns and Impairment at $2.1 million in Q1 2026, $2.8 million in Q4 2025, and $3.2 million in Q3 2025.